Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New synthetic inhibitor to the alternative complement pathway.

N Ikari, Y Sakai, Y Hitomi

    Immunology
    |August 1, 1983
    PubMed
    Summary

    6-amidino-2-naphthyl 4-guanidinobenzoate (FUT-175) inhibits key complement system proteins, including factor B and factor D. This compound specifically targets the Bb fragment, acting as a non-competitive inhibitor of crucial enzymatic activities.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The effect of surgical dissections on blood flow to the tibial tubercle.

    Journal of orthopaedic research : official publication of the Orthopaedic Research Society·2001
    Same author

    [Post-operative intra-arterial chemotherapy for high grade malignant musculoskeletal sarcoma].

    Gan to kagaku ryoho. Cancer & chemotherapy·1993
    Same author

    Effects of an NK1 receptor antagonist, FK888, on constriction and plasma extravasation induced in guinea pig airway by neurokinins and capsaicin.

    European journal of pharmacology·1993
    Same author

    Adenosine A2 receptor antagonist facilitates the reversal of long-term potentiation (depotentiation) of evoked postsynaptic potentials but inhibits that of population spikes in hippocampal CA1 neurons.

    Neuroscience letters·1992
    Same author

    Altered expression of E-cadherin in gastric cancer tissues and carcinomatous fluid.

    British journal of cancer·1992
    Same author

    Augmented arterial wall expression of type-1 plasminogen activator inhibitor induced by thrombosis.

    Arteriosclerosis and thrombosis : a journal of vascular biology·1992

    Area of Science:

    • Biochemistry
    • Immunology
    • Pharmacology

    Background:

    • The complement system is a critical part of innate immunity.
    • Factor B and Factor D are essential serine proteases within the complement cascade.
    • Cobra venom factor (CVF) X Bb is a potent activator of the alternative complement pathway.

    Purpose of the Study:

    • To investigate the inhibitory effects of 6-amidino-2-naphthyl 4-guanidinobenzoate (FUT-175) on complement system enzymes.
    • To determine the specificity and mechanism of FUT-175 inhibition.
    • To assess the potential of FUT-175 as a modulator of complement activity.

    Main Methods:

    • Enzyme activity assays using specific substrates.
    • Hemolytic assays to measure complement-mediated lysis.

    Related Experiment Videos

  • Binding studies to identify target fragments.
  • Determination of inhibitor concentration for 50% inhibition (IC50).

    • Main Results:

    • FUT-175 demonstrated specific binding to the Bb fragment of factor B and CVF X Bb.
    • FUT-175 acted as a non-competitive inhibitor of esterolytic activity mediated by factor B and CVF X Bb.
    • The compound inhibited the hemolytic activity of factor B and the C3 convertase activity of CVF X Bb.
    • FUT-175 also inhibited the factor D-mediated cleavage of factor B.
    • The concentration of FUT-175 required for 50% inhibition ranged from 10(-5) to 10(-4) M.

    Conclusions:

    • FUT-175 is a potent inhibitor of multiple components and activities within the complement cascade.
    • Its specific targeting of the Bb fragment suggests a role in regulating complement activation.
    • FUT-175's inhibitory profile warrants further investigation for therapeutic applications in complement-mediated diseases.